Roivant Sciences operates a decentralized network of specialty pharmaceutical companies, monetizing its R&D pipeline by licensing assets to large-scale partners while retaining royalties on sales.
Investors may view ROIV as a high-risk, high-reward opportunity to capitalize on its vast underutilized asset portfolio that could trigger massive value release through future licensing agreements with top-tier pharma giants. The company's ability to generate billions in non-cash income adjustments and maintain over $2B in liquid assets suggests it has the runway to execute a transformative strategy if key milestones are achieved.
The sharp deterioration in net income from 2024 to 2025, coupled with negative operating cash flows of nearly $840M, signals severe financial distress that could erode shareholder value without immediate external capital. The reliance on a shrinking revenue base of roughly $30M makes the stock vulnerable to market downturns or delays in regulatory approvals for its licensed assets.
Roivant Sciences (ROIV) is a global life sciences company focused on licensing assets from its proprietary portfolio of pharmaceutical and biotechnology companies to third-party partners. The company serves markets across the United States, Europe, and Asia with a portfolio spanning oncology, immunology, metabolic disease, and rare diseases. ROIV generates revenue primarily through upfront payments and milestones associated with these licensed intellectual property rights.
Despite a revenue decline to $29.1M in 2025 compared to previous years, the company reported a massive net profit swing from a $4.23B gain in 2024 to a $-356.7M loss in 2025, reflecting the cyclical nature of milestone-heavy licensing models. Cash flow from operations turned negative at $-839.5M while cash reserves remained robust at $2.73B, though significant outflows occurred in financing and investing activities totaling over $3 billion combined.
The global life sciences sector is increasingly fragmented, with large pharmaceutical companies seeking specialized partners to access niche therapeutic areas like oncology and rare diseases. This trend favors companies like Roivant that can bridge the gap between early-stage discovery and commercialization through strategic licensing partnerships rather than traditional product sales.
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $61.3M | $124.8M | $29.1M |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $61.3M | $124.8M | $29.1M |
| Operating Expenses | $1.24B | $-4.12B | $1.03B |
| Operating Income | $-1.18B | $4.24B | $-1.00B |
| R&D | $525.2M | $501.7M | $550.4M |
| G&A | $600.5M | $687.4M | $591.4M |
| Stock-Based Comp | $217.8M | $199.6M | $289.0M |
| D&A | $18.9M | $22.0M | $14.1M |
| Other OpEx | $110.9M | $-5.31B | $-109.5M |
| Non-Operating Income | $-49.5M | $11.4M | $321.7M |
| Interest Expense | $28.0M | $34.8M | — |
| Pre-Tax Income | $-1.22B | $4.25B | $-681.6M |
| Income Tax | $5.2M | $22.2M | $48.2M |
| Continuing Ops | $-1.23B | $4.23B | $-729.8M |
| Discontinued Ops | $114.6M | $0 | $373.0M |
| Net Income | $-1.12B | $4.23B | $-356.7M |
| Minority Interest | $-106.4M | $-117.7M | $-184.8M |
| Net to Common | $-1.01B | $4.35B | $-172.0M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $1.80B | $6.73B | $5.00B |
| Cash & Equivalents | $1.68B | $6.54B | $2.72B |
| Marketable Securities | — | — | $2.17B |
| Inventory | $2.8M | $35.3M | — |
| Other Current Assets | $119.0M | $160.9M | $113.2M |
| Long-Term Assets | $591.0M | $490.7M | $436.9M |
| PP&E (Net) | $39.1M | $19.1M | $12.1M |
| Intangibles | $144.9M | $137.8M | — |
| Operating Leases | $53.3M | $46.9M | $89.0M |
| Other LT Assets | $353.8M | $286.9M | $335.8M |
| Total Assets | $2.39B | $7.22B | $5.44B |
| Current Liabilities | $272.4M | $266.8M | $149.4M |
| Accounts Payable | $37.8M | $53.2M | $23.7M |
| Current Debt | $40.7M | $12.0M | — |
| Current Leases | $11.7M | $9.9M | $9.8M |
| Other Current Liab | $15.1M | $16.1M | $1.6M |
| Long-Term Liabilities | $509.6M | $507.2M | $100.3M |
| LT Operating Leases | $53.5M | $47.3M | $90.3M |
| Other LT Liab | $456.1M | $459.9M | $10.0M |
| Total Liabilities | $782.0M | $774.0M | $249.7M |
| Shareholders' Equity | $1.61B | $6.45B | $5.19B |
| Paid-In Capital | $4.93B | $5.40B | $4.56B |
| Retained Earnings | $-3.77B | $576.2M | $116.1M |
| AOCI | $-2.6M | $-4.1M | $9.4M |
| Total L&E | $2.39B | $7.22B | $5.44B |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $-1.12B | $4.23B | $-356.7M |
| Non-Cash Adjustments | $209.0M | $-5.15B | $-473.3M |
| Working Capital Changes | $63.1M | $149.0M | $-9.4M |
| Cash from Operations | $-843.4M | $-765.3M | $-839.5M |
| Capital Expenditures | $12.7M | $1.4M | $4.6M |
| Cash from Investing | $-44.3M | $5.20B | $-1.77B |
| Share Buybacks | — | — | $1.29B |
| Cash from Financing | $499.5M | $419.4M | $-1.22B |
| FX Effect | $6.3M | $616.0K | $747.0K |
| Net Change in Cash | $-381.9M | $4.86B | $-3.82B |
| Beginning Cash | $2.07B | $1.69B | $6.51B |
| Ending Cash | $1.69B | $6.55B | $2.73B |
The company's revenue streams are derived from its proprietary portfolio of specialty pharmaceutical entities, which include oncology-focused companies like Alkermes and Immunovant, as well as metabolic disease and rare disease specialists. Revenue is generated through upfront licensing fees, commercial milestones upon asset approval or sales thresholds, and ongoing royalty payments tied to the performance of partner-managed products.
Significant cash burn persists due to high operating expenses and substantial share repurchases, raising concerns about liquidity sustainability given the current revenue base of only $29.1M in 2025. The company faces dilution risk if cash reserves deplete before major licensing deals or milestones materialize, potentially forcing equity issuances at unfavorable valuations. Revenue volatility is high as income relies heavily on one-time milestone payments rather than stable product sales, creating unpredictable quarterly earnings profiles.
Roivant possesses a unique decentralized business model that leverages its own internal research and development capabilities to create specialized pharmaceutical companies without requiring massive capital expenditures for manufacturing facilities. The company benefits from an extensive intellectual property portfolio built over decades, allowing it to license high-value assets to major industry players who have the distribution infrastructure but lack specific niche R&D expertise.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.